Caitlin Costello • UCSD Profiles (original) (raw)

  1. TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial. Nat Commun. 2025 Nov 24; 16(1):10050. Tseng H, Dholaria B, Cranert SA, Richter M, Marquez KS, Cho BS, Bacong A, McArthur K, Eskew JD, McCaigue J, Haag S, Krasny A, Solimine B, Coffey MJ, Loyola A, Kwong J, Shune L, Kin A, Costello CL, Kocoglu MH, Ramakrishnan A, Namini H, Martin CE, Belani R, Coronella J, Shedlock DJ. PMID: 41285709; PMCID: PMC12644732.
  2. Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience. Biomedicines. 2024 Dec 27; 13(1). Trando A, Ghamsari F, Yeung P, Costello C, Saunders I, Jeong AR. PMID: 39857619; PMCID: PMC11759176.
    View in: PubMed Mentions:
  3. A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and review of the English literature. Br J Haematol. 2024 Jul; 205(1):364-367. Wang HY, Louis HMS, Costello CL, Murray SS, Dell'Aquila ML. PMID: 38735761.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  4. In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. Future Oncol. 2024 Jan; 20(3):131-143. Rifkin RM, Costello CL, Birhiray RE, Kambhampati S, Richter J, Abonour R, Lee HC, Stokes M, Ren K, Stull DM, Cherepanov D, Bogard K, Noga SJ, Girnius S. PMID: 37807952.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  5. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 10; 29(10):2570-2576. Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM. PMID: 37783970; PMCID: PMC10579053.
    View in: PubMed Mentions: 66 Fields:
    Translation:HumansCellsCTClinical Trials
  6. Heart-liver-kidney transplantation for AL amyloidosis using normothermic recovery and storage from a donor following circulatory death: Short-term outcome in a first-in-world experience. Am J Transplant. 2023 02; 23(2):291-293. Brubaker AL, Urey MA, Taj R, Parekh JR, Berumen J, Kearns M, Shah M, Khan A, Kono Y, Ajmera V, Barman P, Tran H, Adler ED, Silva Enciso J, Asimakopoulos F, Costello C, Bower R, Sanchez R, Pretorius V, Schnickel GT. PMID: 36804136.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  7. Newly diagnosed multiple myeloma: making sense of the menu. Hematology Am Soc Hematol Educ Program. 2022 12 09; 2022(1):539-550. Costello CL. PMID: 36485145; PMCID: PMC9820388.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  8. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2023 03; 23(3):e171-e181. Thompson MA, Boccadoro M, Leleu X, Vela-Ojeda J, van Rhee F, Weisel KC, Rifkin RM, Usmani SZ, Hájek R, Cook G, Abonour R, Armour M, Morgan KE, Yeh SP, Costello CL, Berdeja JG, Davies FE, Zonder JA, Lee HC, Omel J, Spencer A, Terpos E, Hungria VTM, Puig N, Fu C, Ferrari RH, Ren K, Stull DM, Chari A. PMID: 36641358.
    View in: PubMed Mentions: 4 Fields:
    Translation:HumansPHPublic Health
  9. Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells. STAR Protoc. 2021 06 18; 2(2):100565. Vora AA, Mondala PK, Costello C, MacLeod AR, Crews LA. PMID: 34136833; PMCID: PMC8176358.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansCells
  10. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens. Transfusion. 2021 07; 61(7):2054-2063. Phou S, Costello C, Kopko PM, Allen ES. PMID: 33960433.
    View in: PubMed Mentions: 4 Fields:
    Translation:HumansCells
  11. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021 Jul; 17(19):2499-2512. Hájek R, Minarík J, Straub J, Pour L, Jungova A, Berdeja JG, Boccadoro M, Brozova L, Spencer A, van Rhee F, Vela-Ojeda J, Thompson MA, Abonour R, Chari A, Cook G, Costello CL, Davies FE, Hungria VT, Lee HC, Leleu X, Puig N, Rifkin RM, Terpos E, Usmani SZ, Weisel KC, Zonder JA, Barinová M, Kuhn M, Šilar J, Cápková L, Galvez K, Lu J, Elliott J, Stull DM, Ren K, Maisnar V. PMID: 33769076.
    View in: PubMed Mentions: 13 Fields:
    Translation:Humans
  12. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021 02 18; 11(2):40. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. PMID: 33602913; PMCID: PMC7891472.
    View in: PubMed Mentions: 58 Fields:
    Translation:Humans
  13. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell Stem Cell. 2021 04 01; 28(4):623-636.e9. Mondala PK, Vora AA, Zhou T, Lazzari E, Ladel L, Luo X, Kim Y, Costello C, MacLeod AR, Jamieson CHM, Crews LA. PMID: 33476575; PMCID: PMC8026723.
    View in: PubMed Mentions: 39 Fields:
    Translation:HumansAnimalsCells
  14. Supportive Care in Multiple Myeloma. Curr Hematol Malig Rep. 2020 04; 15(2):56-61. Guzdar A, Costello C. PMID: 32172361.
    View in: PubMed Mentions: 10 Fields:
    Translation:Humans
  15. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression. Proc Natl Acad Sci U S A. 2019 12 03; 116(49):24881-24891. Banerjee S, Wei T, Wang J, Lee JJ, Gutierrez HL, Chapman O, Wiley SE, Mayfield JE, Tandon V, Juarez EF, Chavez L, Liang R, Sah RL, Costello C, Mesirov JP, de la Vega L, Cooper KL, Dixon JE, Xiao J, Lei X. PMID: 31754034; PMCID: PMC6900511.
    View in: PubMed Mentions: 34 Fields:
    Translation:HumansAnimalsCells
  16. The future of checkpoint inhibition in multiple myeloma? Lancet Haematol. 2019 09; 6(9):e439-e440. Costello C. PMID: 31327688.
    View in: PubMed Mentions: 11 Fields:
    Translation:Humans
  17. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncol. 2019 May; 15(13):1411-1428. Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V. PMID: 30816809; PMCID: PMC6854441.
    View in: PubMed Mentions: 15 Fields:
    Translation:Humans
  18. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Br J Haematol. 2018 03; 180(6):821-830. Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R. PMID: 29435979; PMCID: PMC5873373.
    View in: PubMed Mentions: 21 Fields:
    Translation:HumansCTClinical Trials
  19. Therapy sequencing strategies in multiple myeloma: who, what and why? Future Oncol. 2018 01; 14(2):95-99. Costello C, Mikhael JR. PMID: 29219615.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  20. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat Commun. 2017 12 04; 8(1):1922. Lazzari E, Mondala PK, Santos ND, Miller AC, Pineda G, Jiang Q, Leu H, Ali SA, Ganesan AP, Wu CN, Costello C, Minden M, Chiaramonte R, Stewart AK, Crews LA, Jamieson CHM. PMID: 29203771; PMCID: PMC5715072.
    View in: PubMed Mentions: 79 Fields:
    Translation:HumansAnimalsCells
  21. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. PMID: 28681041; PMCID: PMC5495179.
    View in: PubMed Mentions: 15 Fields:
  22. An update on the role of daratumumab in the treatment of multiple myeloma. Ther Adv Hematol. 2017 Jan; 8(1):28-37. Costello C. PMID: 28042457; PMCID: PMC5167079.
    View in: PubMed Mentions: 16
  23. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ, Leukemia and Lymphoma Society Blood Cancer Research Partnership. PMID: 27410923; PMCID: PMC5149459.
    View in: PubMed Mentions: 328 Fields:
    Translation:HumansCellsCTClinical Trials
  24. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R, National Comprehensive Cancer Network. PMID: 26553768; PMCID: PMC4891187.
    View in: PubMed Mentions: 35 Fields:
    Translation:Humans
  25. Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012 Feb; 18(2):257-64. Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED. PMID: 21736867.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs